Biocryst Pharmaceuticals (BCRX) Free Cash Flow (2010 - 2026)
Biocryst Pharmaceuticals' (BCRX) quarterly Free Cash Flow came in at -$62.4 million in Q1 2026, down 126.77% YoY from $233.1 million in Q1 2025, and down 121.3% on a QoQ basis from $293.0 million in Q4 2025.
Biocryst Pharmaceuticals (BCRX) Free Cash Flow (2010 - 2026) Analysis & Trends
Biocryst Pharmaceuticals (BCRX) has 17 years of Free Cash Flow data on file, last reported at -$62.4 million in Q1 2026.
- Quarterly Free Cash Flow fell 126.77% year-over-year to -$62.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $311.9 million (up 1317.42% YoY) and the FY2025 annual result came in at $346.8 million, up 766.59% from the prior year.
- Free Cash Flow slipped to -$62.4 million in Q1 2026, from $293.0 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $293.0 million in Q4 2025 to a low of -$78.2 million in Q1 2022.
- A 5-year average of -$1.5 million and a median of -$20.9 million in 2023 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2025 — Free Cash Flow soared 6250.67% — and 2026, when it tumbled 126.77%.
- Tracing BCRX's Free Cash Flow over 5 years: stood at -$24.4 million in 2022, then surged by 70.03% to -$7.3 million in 2023, then soared by 34.78% to -$4.8 million in 2024, then soared by 6250.67% to $293.0 million in 2025, then slumped by 121.3% to -$62.4 million in 2026.
- The last three Free Cash Flow figures came in at -$62.4 million (Q1 2026), $293.0 million (Q4 2025), and $41.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 307.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 538.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 1.14 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 205.60 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 329.00 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 128.60 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 244.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Biocryst Pharmaceuticals | 2.46 Bn | 2.11 Bn | 214.41 Mn | 104.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 104.34 Mn |
| Jun 30, 2026 | 104.34 Mn |
| Mar 31, 2026 | -62.40 Mn |
| Mar 31, 2026 | -62.40 Mn |
| Dec 31, 2025 | 293.02 Mn |
| Dec 31, 2025 | 293.02 Mn |
| Sep 30, 2025 | 41.03 Mn |
| Sep 30, 2025 | 41.03 Mn |
| Jun 30, 2025 | 40.23 Mn |
| Jun 30, 2025 | 40.23 Mn |
| Mar 31, 2025 | -27.52 Mn |
| Mar 31, 2025 | -27.52 Mn |
| Dec 31, 2024 | -4.76 Mn |
| Dec 31, 2024 | -4.76 Mn |
| Sep 30, 2024 | 7.80 Mn |
| Sep 30, 2024 | 7.80 Mn |
| Jun 30, 2024 | -1.13 Mn |
| Jun 30, 2024 | -1.13 Mn |
| Mar 31, 2024 | -53.92 Mn |
| Mar 31, 2024 | -53.92 Mn |